Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00231413 · ClinicalTrials.gov registry record · Phase 2
Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 383
- Enrollment target
NCT00231413 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 383 participants.
The verdict
NCT00231413, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 383 participants
- Enrollment target
Study Summary
Human Papilloma viruses (HPV) are viruses that cause infections of the skin and genitals in men and women. Several types of HPV infection are transmitted by sexual activity and, in women, can infect the cervix (part of the uterus or womb). This infection, if it persists, can lead over a long period of time to cancer of the cervix in women. In collaboration with MedImmune Inc., GlaxoSmithKline Biologicals has developed a HPV vaccine against the oncogenic types HPV-16 and HPV-18 formulated with the adjuvant AS04. GSK Biologicals is also evaluating novel HPV vaccine formulations.This study will evaluate the immunogenicity and safety of a novel GSK Biologicals HPV vaccine in women 18-25 years of age at study start. Approximately 376 study subjects will receive the novel HPV vaccine or the control vaccine administered intramuscularly according to a 0-1-6 month schedule.
Interventions
- BIOLOGICAL HPV 16/18 L1 AS04
- BIOLOGICAL HPV-16/18/31/45 L1 AS04 Formulation 1
- BIOLOGICAL HPV-16/18/31/45 L1 AS04 Formulation 2
- BIOLOGICAL HPV-16/18/31/45 L1 AS04 Formulation 3
- BIOLOGICAL HPV-16/18/31/45 L1 AS04 Formulation 4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 383 participants |
| Start Date | 2005-03-04 |
| Est. Completion | 2006-03-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00231413
The ClinicalTrials.gov registry entry for NCT00231413 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 383 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which HPV 16/18 L1 AS04 is the first listed.
NCT00231413 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00231413 about?
NCT00231413 is a clinical study titled "Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.". Human Papilloma viruses (HPV) are viruses that cause infections of the skin and genitals in men and women. Several types of HPV infection are transmitted by sexual activity and, in women, can infect the cervix (part of the uterus or womb). This infection, if it persists, can lead over a long period ...
What is the current status of trial NCT00231413?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 383 participants. The study started on 2005-03-04. Estimated completion is 2006-03-27.
What interventions are being tested in trial NCT00231413?
The interventions under investigation include: HPV 16/18 L1 AS04 (BIOLOGICAL), HPV-16/18/31/45 L1 AS04 Formulation 1 (BIOLOGICAL), HPV-16/18/31/45 L1 AS04 Formulation 2 (BIOLOGICAL), HPV-16/18/31/45 L1 AS04 Formulation 3 (BIOLOGICAL), HPV-16/18/31/45 L1 AS04 Formulation 4 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00231413?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.